Screener
Kailera Therapeutics KLRA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $70,873 | $10,130 |
| General and administrative | 13,787 | 10,328 |
| Total operating expenses | 84,660 | 20,458 |
| Loss from operations | (84,660) | (20,458) |
| Other income | ||
| Interest income | 5,716 | 1,675 |
| Other income, net | 79 | 800 |
| Total other income | 5,795 | 2,475 |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's operating income?
- Kailera Therapeutics (KLRA) reported operating income of -$84.66M in Q1 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Kailera Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude